Neurotrophic factors as a therapeutic target for Parkinson's disease

  title={Neurotrophic factors as a therapeutic target for Parkinson's disease},
  author={Jonathan Rhys Evans and Roger A. Barker},
  journal={Expert Opinion on Therapeutic Targets},
  pages={437 - 447}
  • J. Evans, R. Barker
  • Published 18 March 2008
  • Medicine, Biology, Psychology
  • Expert Opinion on Therapeutic Targets
Background: The search for therapeutic agents that might alter the disease course in Parkinson's disease (PD) is ongoing. One area of particular interest involves neurotrophic factors (NTFs), with those of the glial cell line-derived neurotrophic factor (GDNF) family showing greatest promise. The safety and efficacy of these therapies has recently come into question. Furthermore, many of the key questions pertaining to such therapies, such as the optimal method of delivery, timing of treatment… 

Parkinson's disease and growth factors - are they the answer?

  • R. Barker
  • Biology, Psychology
    Parkinsonism & related disorders
  • 2009

Title The potential of neurotrophic factors for the treatment of Parkinson ' s disease

The potential of Neurotrophic Factors for the Treatment of Parkinson’s Disease is explored.

Novel Approach to Stem Cell Therapy in Parkinson's Disease.

This is a single-center, open label, dose escalating 12-month study with a 5-year follow-up evaluating a number of objective and patient-reported safety and efficacy measures.

Current status of clinical trials of neural transplantation in Parkinson's disease.

Repairing the parkinsonian brain with neurotrophic factors

alpha-Synuclein: a therapeutic target for Parkinson's disease?

Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

These findings support the neurorestorative role of VEGF+GDNF in the dopaminergic system and the synergistic effect between both factors.

Cell Therapy for Parkinson’s Disease: Status and Perspectives

Current status and crucial issues that remain to be resolved are discussed to develop cell replacement into an effective and safe therapy for Parkinson's disease.

Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.

The induced bone marrow-derived mesenchymal stem cells have a therapeutic potential for neurodegenerative processes and diseases, both by the NTFs secretion and by the migratory trait toward the diseased tissue.



The expanding role of BDNF: a therapeutic target for Alzheimer's disease?

It appears clear that BDNF is implicated in the mechanism of action of drugs that improve cognitive deficits in animal models of AD and in AD patients, and this review will focus on different pharmacological interventions currently in use or drugs under development that interfere with the expression of the trophic factor brain-derived neurotrophic factor.

In vivo gene delivery of glial cell line–derived neurotrophic factor for Parkinson's disease

This review focuses on in vivo gene delivery of glial cell line—derived neurotrophic factor (GDNF) as a neuroprotective strategy for PD.

Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.

This review presents an outline of the studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future.

Crossroads in GDNF therapy for Parkinson's disease

A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined.

GDNF delivery for Parkinson's disease.

GDNF infusion over 6-months did not confer the predetermined level of clinical benefit to patients with PD despite increased 18F-dopa uptake surrounding the catheter tip, and it is possible that technical differences between this trial and the positive open label studies contributed to this negative outcome.

Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study.

A phase I study evaluating the safety, feasibility, and tolerability of intracerebral administration of ciliary neurotrophic factor (CNTF) in subjects with Huntington's disease shows the need for improving the technique.

GDNF in Parkinson disease: An object lesson in the tyranny of type II

Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

Positron emission tomography scans of [18F]dopamine uptake showed a significant 28% increase in putamen dopamine storage after 18 months, suggesting a direct effect of GDNF on dopamine function, and warrants careful examination ofGDNF as a treatment for Parkinson disease.

GDNF family receptor complexes are emerging drug targets.